Aptar Digital Health recently announced a major strategic partnership. Specifically, they teamed up with Enable Injections, Inc. Enable is a prominent healthcare innovation company. They actively manufacture the enFuse® On-Body Delivery System. Now, Aptar serves as Enable’s preferred partner. Together, they will launch a new digital health solution. This companion tool directly supports the enFuse® system. Furthermore, it clearly guides patients and caregivers through complex injections. It also boosts user engagement before, during, and after treatment.
Through this alliance, Aptar will deliver a comprehensive platform. This companion digital health solution significantly improves the patient experience. Additionally, it strongly supports vital adherence-related medical programs. The system provides clear, step-by-step injection guidance. Moreover, it actively tracks patient-reported outcomes and daily symptoms. Consequently, this tool empowers patients with greater treatment control.
Scaling Smart Healthcare Delivery
Developers built this platform on a highly flexible architecture. Therefore, it deploys seamlessly alongside the enFuse® system. This allows pharmaceutical partners to maximize overall therapy value. The digital health solution easily evolves across the drug lifecycle. Importantly, it readily supports clinical trials and full commercialization. It perfectly aligns with modern development and product launch strategies.
The software securely captures remote medication adherence data. It then shares this information via advanced analytics dashboards. These robust tools generate actionable insights for clinical development. Furthermore, they heavily support launch readiness and real-world application. The modular design aids pharmaceutical partners quite significantly. They can easily integrate specific digital components as needed. Ultimately, combining device data with patient insights drives better medical decisions.
“This collaboration seeks to enhance the treatment experience of patients beyond the moment of injection,” said Michael D. Hooven, Chairman and CEO of Enable Injections. “Together, we will combine innovative drug delivery with digital support tools. This can help patients remain engaged in their therapy and enable healthcare providers to better understand and support each patient’s journey.”
“We are excited to partner with Enable Injections to help bring the next generation of drug delivery solutions to life,” said Damien McKeon, SVP Strategic Partnerships, Aptar Digital Health. “Large-volume biologic therapies are increasingly used to treat complex chronic conditions. They often require long-term adherence to achieve optimal outcomes. Digital solutions supporting treatment tracking and patient engagement can help address common adherence challenges associated with self-administration.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
